Lifeline Biotechnologies, Inc. Analyzes Patient Data to Make First Warning System™ More User Friendly for Women

Business Wire,  Dec 17, 2007  

• E-mail
• Print
• Link

RENO, Nev. -- Lifeline Biotechnologies, Inc. (OTCPK: LLBT) today announced that the Company has recently provided patient cases to Nanyang Technical University to aid in the development of the First Warning System's (FWS) interpretive analytical system. One objective is to make it more user friendly for women to assist in the detection of breast cancer.

Originally, the FWS was worn by women for 48 hours, with eight sensors on each breast. This length of time caused issues because the longer the testing period, the more the likelihood women would accidentally loosen a sensor and send faulty data. After analyzing the patient cases, Lifeline, along with the work at Nanyang Technical University, has been working to reduce the testing period to 24 hours or less, which will make it more user friendly for women and increase the accuracy of the FWS.

"We believe that shortening the time that women have to wear the device will provide more comfort and not interrupt their daily activities. Our enhancements to the software will enable us to cut down the testing time in half, possibly less, and make the detection of breast cancer an easier process," stated Jim Holmes, CEO of Lifeline Biotechnologies, Inc.

Lifeline Biotechnologies is in the process of securing FDA clearance, via a 510(k) for its First Warning System, and will continue to update its shareholders regarding its progress on a regular basis.

About Lifeline Biotechnologies, Inc:

Lifeline Biotechnologies, Inc. is an innovative medical technology company that is focused on completing the development of the First Warning System[TM], which was designed to assist in the early detection of breast cancer. Of the approximately $138 billion spent on cancer each year, Lifeline could potentially save the healthcare industry up to $4.1 billion annually, assuming the following are successfully completed: the development of the First Warning System[TM], the completion of clinical trials and FDA pre-marketing clearance. Lifeline competes in the money markets for funds to support the development of its product. The cost of funds, for early stage companies like Lifeline, are expensive and the terms have been, and may continue to be, dilutive.

Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.

COPYRIGHT 2007 Business Wire
COPYRIGHT 2008 Gale, Cengage Learning